The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Abstract
BACKGROUND: Eplerenone, a selective aldosterone blocker (SAB) that is highly specific for the aldosterone receptor, has the potential to be efficacious in the treatment of hypertension. METHODS: This 8-week, multicenter, double-blind, placebo-controlled trial assessed the efficacy, safety, and tolerability of eplerenone in eligible patients randomized to eplerenone 50, 100, or 400 mg once daily; eplerenone 25, 50, or 200 mg twice daily; spironolactone 50 mg twice daily; or placebo. The primary efficacy variable was the adjusted mean change in baseline to final visit for seated diastolic blood pressure (DBP). RESULTS: Of 417 randomized patients, 409 were evaluated for efficacy. The adjusted mean change from baseline to final visit in seated and standing systolic blood pressure (SBP) and DBP was significantly greater (P < .05) in all eplerenone groups than in the placebo group. The adjusted mean change in 24-h ambulatory blood pressure monitoring (ABPM) measurements of SBP and DBP also documented a 24-h duration significantly greater (P < .05) than placebo in eplerenone-treated patients. For all measurements, the antihypertensive effect of eplerenone increased in a dose-response fashion. Eplerenone (100 mg) reduced BP by 75% compared with spironolactone (100 mg) and had an adverse events incidence rate similar to placebo. No antiandrogenic or progestational effects or clinically relevant safety issues were observed in eplerenone-treated patients. However, one spironolactone-treated patient reported menstrual irregularities. CONCLUSIONS: Eplerenone doses of 50 to 400 mg once daily are well tolerated and effective in reducing BP in patients with mild-to-moderate hypertension during a 24-h period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Weber, K. T., & Brilla, C. G. (1991) · Circulation · doi:10.1161/01.cir.83.6.1849 · Cited by 2,027
Remodeling of the rat right and left ventricles in experimental hypertension.
Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S., & Weber, K. T. (1990) · Circulation Research · doi:10.1161/01.res.67.6.1355 · Cited by 674
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 496
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339
Efficacy and tolerance of spironolactone in essential hypertension
Jeunemaitre, X., Chatellier, G., Kreft-Jais, C., Charru, A., Devries, C., Plouin, P.-F., Corvol, P., & Menard, J. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)91030-7 · Cited by 276
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
Struthers, A. D. (1996) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(96)80009-1 · Cited by 225
Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology
Delyani, J. A. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00983.x · Cited by 206
Brunner, H. R., Chang, P., Wallach, R., Sealey, J. E., & Laragh, J. H. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106797 · Cited by 195
Cited by
Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4061 · Cited by 2,925
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
Efficacy of low-dose spironolactone in subjects with resistant hypertension
Nishizaka, M. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)01032-x · Cited by 502
Metadata
- Authors
- Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. J.
- Venue
- American Journal of Hypertension
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-08-01
- Volume
- 15
- Issue
- 8
- Pages
- 709-716
- ISSN
- 0895-7061 (ISSN-L)
- 1941-7225
- OpenAlex
- W2125226019
- Cited by
- 388
- References
- 14
- FWCI
- 15.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. https://app.cochat.ai/papers/10.1016/s0895-7061(02)02957-6
- The paper
- Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. J. (2002). Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. American Journal of Hypertension. https://doi.org/10.1016/s0895-7061(02)02957-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.